Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Lindström, Ulf ; Glintborg, Bente ; Di Giuseppe, Daniela ; Schjødt Jørgensen, Tanja ; Gudbjornsson, Bjorn ; Lederballe Grøn, Kathrine ; Aarrestad Provan, Sella ; Michelsen, Brigitte ; Lund Hetland, Merete ; Wallman, Johan K ; Nordström, Dan ; Trokovic, Nina ; Love, Thorvardur Jon ; Krogh, Niels Steen ; Askling, Johan ; Jacobsson, Lennart T H ; Kristensen, Lars Erik. / Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. In: Rheumatology (Oxford, England). 2021 ; Vol. 60, No. 8. pp. 3635-3645.

Bibtex

@article{368b151b559e4f2b89907b4b592fb9f3,
title = "Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis",
abstract = "OBJECTIVES: To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA.METHODS: All patients with PsA starting secukinumab or a TNFi in 2015-2018 were identified in the biologic registers of the Nordic countries. Data on comorbidities were linked from national registers. One-year treatment retention and hazard ratios (HRs) for treatment discontinuation were calculated. The proportion achieving a 6 month 28-joint Disease Activity Index for Psoriatic Arthritis (DAPSA28) remission was determined together with odds ratios (ORs) for remission (logistic regression). Both HRs and ORs were calculated with adalimumab as the reference and adjusted for baseline characteristics and concurrent comorbidities. All analyses were stratified by the line of biologic treatment (first, second, third+).RESULTS: We identified 6143 patients contributing 8307 treatment courses (secukinumab, 1227; adalimumab, 1367). Secukinumab was rarely used as the first biologic, otherwise baseline characteristics were similar. No clinically significant differences in treatment retention or response rates were observed for secukinumab vs adalimumab. The adjusted HRs for discontinuation per the first, second and third line of treatment were 0.98 (95% CI 0.68, 1.41), 0.94 (0.70, 1.26) and 1.07 (0.84, 1.36), respectively. The ORs for DAPSA28 remission in the first, second and third line of treatment were 0.62 (95% CI 0.30, 1.28), 0.85 (0.41, 1.78) and 0.74 (0.36, 1.51), respectively. In the subset of patients previously failing a TNFi due to ineffectiveness, the results were similar.CONCLUSION: No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.",
keywords = "Adult, Aged, Antibodies, Monoclonal, Humanized/therapeutic use, Arthritis, Psoriatic/drug therapy, Female, Humans, Male, Medication Adherence/statistics & numerical data, Middle Aged, Treatment Outcome, Tumor Necrosis Factor Inhibitors/therapeutic use, treatment, secukinumab, adalimumab, response, psoriatic arthritis, retention",
author = "Ulf Lindstr{\"o}m and Bente Glintborg and {Di Giuseppe}, Daniela and {Schj{\o}dt J{\o}rgensen}, Tanja and Bjorn Gudbjornsson and {Lederballe Gr{\o}n}, Kathrine and {Aarrestad Provan}, Sella and Brigitte Michelsen and {Lund Hetland}, Merete and Wallman, {Johan K} and Dan Nordstr{\"o}m and Nina Trokovic and Love, {Thorvardur Jon} and Krogh, {Niels Steen} and Johan Askling and Jacobsson, {Lennart T H} and Kristensen, {Lars Erik}",
note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2021",
month = aug,
day = "2",
doi = "10.1093/rheumatology/keaa825",
language = "English",
volume = "60",
pages = "3635--3645",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "8",

}

RIS

TY - JOUR

T1 - Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

AU - Lindström, Ulf

AU - Glintborg, Bente

AU - Di Giuseppe, Daniela

AU - Schjødt Jørgensen, Tanja

AU - Gudbjornsson, Bjorn

AU - Lederballe Grøn, Kathrine

AU - Aarrestad Provan, Sella

AU - Michelsen, Brigitte

AU - Lund Hetland, Merete

AU - Wallman, Johan K

AU - Nordström, Dan

AU - Trokovic, Nina

AU - Love, Thorvardur Jon

AU - Krogh, Niels Steen

AU - Askling, Johan

AU - Jacobsson, Lennart T H

AU - Kristensen, Lars Erik

N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2021/8/2

Y1 - 2021/8/2

N2 - OBJECTIVES: To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA.METHODS: All patients with PsA starting secukinumab or a TNFi in 2015-2018 were identified in the biologic registers of the Nordic countries. Data on comorbidities were linked from national registers. One-year treatment retention and hazard ratios (HRs) for treatment discontinuation were calculated. The proportion achieving a 6 month 28-joint Disease Activity Index for Psoriatic Arthritis (DAPSA28) remission was determined together with odds ratios (ORs) for remission (logistic regression). Both HRs and ORs were calculated with adalimumab as the reference and adjusted for baseline characteristics and concurrent comorbidities. All analyses were stratified by the line of biologic treatment (first, second, third+).RESULTS: We identified 6143 patients contributing 8307 treatment courses (secukinumab, 1227; adalimumab, 1367). Secukinumab was rarely used as the first biologic, otherwise baseline characteristics were similar. No clinically significant differences in treatment retention or response rates were observed for secukinumab vs adalimumab. The adjusted HRs for discontinuation per the first, second and third line of treatment were 0.98 (95% CI 0.68, 1.41), 0.94 (0.70, 1.26) and 1.07 (0.84, 1.36), respectively. The ORs for DAPSA28 remission in the first, second and third line of treatment were 0.62 (95% CI 0.30, 1.28), 0.85 (0.41, 1.78) and 0.74 (0.36, 1.51), respectively. In the subset of patients previously failing a TNFi due to ineffectiveness, the results were similar.CONCLUSION: No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.

AB - OBJECTIVES: To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA.METHODS: All patients with PsA starting secukinumab or a TNFi in 2015-2018 were identified in the biologic registers of the Nordic countries. Data on comorbidities were linked from national registers. One-year treatment retention and hazard ratios (HRs) for treatment discontinuation were calculated. The proportion achieving a 6 month 28-joint Disease Activity Index for Psoriatic Arthritis (DAPSA28) remission was determined together with odds ratios (ORs) for remission (logistic regression). Both HRs and ORs were calculated with adalimumab as the reference and adjusted for baseline characteristics and concurrent comorbidities. All analyses were stratified by the line of biologic treatment (first, second, third+).RESULTS: We identified 6143 patients contributing 8307 treatment courses (secukinumab, 1227; adalimumab, 1367). Secukinumab was rarely used as the first biologic, otherwise baseline characteristics were similar. No clinically significant differences in treatment retention or response rates were observed for secukinumab vs adalimumab. The adjusted HRs for discontinuation per the first, second and third line of treatment were 0.98 (95% CI 0.68, 1.41), 0.94 (0.70, 1.26) and 1.07 (0.84, 1.36), respectively. The ORs for DAPSA28 remission in the first, second and third line of treatment were 0.62 (95% CI 0.30, 1.28), 0.85 (0.41, 1.78) and 0.74 (0.36, 1.51), respectively. In the subset of patients previously failing a TNFi due to ineffectiveness, the results were similar.CONCLUSION: No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Arthritis, Psoriatic/drug therapy

KW - Female

KW - Humans

KW - Male

KW - Medication Adherence/statistics & numerical data

KW - Middle Aged

KW - Treatment Outcome

KW - Tumor Necrosis Factor Inhibitors/therapeutic use

KW - treatment

KW - secukinumab

KW - adalimumab

KW - response

KW - psoriatic arthritis

KW - retention

UR - http://www.scopus.com/inward/record.url?scp=85113715244&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keaa825

DO - 10.1093/rheumatology/keaa825

M3 - Journal article

C2 - 33367900

VL - 60

SP - 3635

EP - 3645

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 8

ER -

ID: 67549697